Galunisertib + Gemcitabine + Placebo
Phase 1/2Completed 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neoplasms
Conditions
Neoplasms, Neoplasm Metastasis, Pancreatic Cancer
Trial Timeline
Jun 1, 2011 → Dec 1, 2016
NCT ID
NCT01373164About Galunisertib + Gemcitabine + Placebo
Galunisertib + Gemcitabine + Placebo is a phase 1/2 stage product being developed by Eli Lilly for Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT01373164. Target conditions include Neoplasms, Neoplasm Metastasis, Pancreatic Cancer.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01373164 | Phase 1/2 | Completed |
Competing Products
20 competing products in Neoplasms